Corvus Pharmaceuticals
CRVS
41 hedge funds and large institutions have $18.1M invested in Corvus Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 11 closing their positions.
0% more capital invested
Capital invested by funds: $18.1M → $18.1M (+$56.7K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.63% less ownership
Funds ownership: 47.47% → 45.85% (-1.6%)
15% less funds holding
Funds holding: 48 → 41 (-7)
26% less call options, than puts
Call options by funds: $23K | Put options by funds: $31K
46% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 13
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$486K |
| 2 |
Morgan Stanley
New York
|
+$29.5K |
| 3 |
CB
Commerce Bank
Kansas City,
Missouri
|
+$17.7K |
| 4 |
VF
Virtu Financial
New York
|
+$16.6K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$8.36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$324K |
| 2 |
Renaissance Technologies
New York
|
-$289K |
| 3 |
Two Sigma Advisers
New York
|
-$195K |
| 4 |
Two Sigma Investments
New York
|
-$131K |
| 5 |
TI
Telemetry Investments
New York
|
-$117K |
CRVS Hedge Fund Activity: Q4 2022 in Review
41 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q4 2022, worth a combined $18.1M — up 0.31% from $18.1M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CRVS and 5 opened new positions — a net loss of 6 holders — while 13 trimmed existing stakes and 7 added.
The largest buyer was Discovery Capital Management, opening a new position worth an estimated $486K. The largest seller was Millennium Management, cutting an estimated $324K.
- 41 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q4 2022, down from 48 in Q3 2022.
- Funds reported $18.1M of Corvus Pharmaceuticals stock for Q4 2022, up 0.31% quarter-over-quarter.
- 5 funds opened new Corvus Pharmaceuticals positions in Q4 2022 and 11 closed out, a net change of -6 holders.
- The largest Corvus Pharmaceuticals buyer in Q4 2022 was Discovery Capital Management, an estimated $486K added.
- The largest Corvus Pharmaceuticals seller in Q4 2022 was Millennium Management, an estimated $324K sold.
Based on aggregated 13F filings for Q4 2022.